[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"condition:aggressive-non-hodgkin-lymphoma":3},{"name":4,"total":5,"recruiting":5,"trials":6,"biomarkers":21,"states":22},"Aggressive Non-Hodgkin Lymphoma",2,[7,15],{"nct_id":8,"title":9,"phases":10,"status":12,"updated_at":13,"content_modified":14},"NCT04288726","Allogeneic CD30.CAR-EBVSTs in Patients With Relapsed or Refractory CD30-Positive Lymphomas",[11],"Phase 1","RECRUITING","2026-08-26T02:16:47.762107Z","2026-05-05T02:43:28.120885Z",{"nct_id":16,"title":17,"phases":18,"status":12,"updated_at":19,"content_modified":20},"NCT04231877","Polatuzumab Vedotin and Combination Chemotherapy With or Without Glofitamab for the Treatment of Untreated Aggressive Large B-cell Lymphoma",[11],"2026-08-03T01:58:01.892442Z","2026-05-05T02:43:28.077600Z",[],[]]